The prescription pattern for coronary artery disease in tertiary care hospitals

Future Journal of Pharmaceuticals and Health Sciences Pub Date : 2023-11-24 DOI:10.26452/fjphs.v3i4.525

Gautham Chakra R, Chandana Sai Y, Jyoshna V, Likhitha K, Tejeswini N, Iswarya N, Naga Lakshmi N

{"title":"The prescription pattern for coronary artery disease in tertiary care hospitals","authors":"Gautham Chakra R, Chandana Sai Y, Jyoshna V, Likhitha K, Tejeswini N, Iswarya N, Naga Lakshmi N","doi":"10.26452/fjphs.v3i4.525","DOIUrl":null,"url":null,"abstract":"The study aims to assess the current prescribing patterns for drugs managing Coronary Heart Disease (CHD) at the designated site to promote rational drug use in a specialized population. Conducted in the Medicine ward over six months, this observational retrospective study focused on patients consulting cardiologists for cardiac issues. Among lipid-lowering agents, rosuvastatin was the most prescribed (52.84%), followed by atorvastatin (43.15%). Anti-hypertensive agents were widely used, with beta-blockers, ACE inhibitors, and diuretics being popular choices. Adrenergic receptor blockers were common for hypertension, with metoprolol (55.7%) and bisoprolol (10.8%) frequently prescribed. ACE inhibitors, particularly Enalapril (65.6%), dominated prescriptions. Diuretics, including eplerenone (37.2%) and furosemide (33.3%), ranked third. The majority of patients were male, potentially linked to smoking and alcohol habits. Analysis revealed the prevalence of statins and anti-atherogenic agents in cardiovascular prescriptions. Beta-blockers, ACE inhibitors, and diuretics were prominent in managing hypertension.Top of Form","PeriodicalId":503124,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"66 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceuticals and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26452/fjphs.v3i4.525","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The study aims to assess the current prescribing patterns for drugs managing Coronary Heart Disease (CHD) at the designated site to promote rational drug use in a specialized population. Conducted in the Medicine ward over six months, this observational retrospective study focused on patients consulting cardiologists for cardiac issues. Among lipid-lowering agents, rosuvastatin was the most prescribed (52.84%), followed by atorvastatin (43.15%). Anti-hypertensive agents were widely used, with beta-blockers, ACE inhibitors, and diuretics being popular choices. Adrenergic receptor blockers were common for hypertension, with metoprolol (55.7%) and bisoprolol (10.8%) frequently prescribed. ACE inhibitors, particularly Enalapril (65.6%), dominated prescriptions. Diuretics, including eplerenone (37.2%) and furosemide (33.3%), ranked third. The majority of patients were male, potentially linked to smoking and alcohol habits. Analysis revealed the prevalence of statins and anti-atherogenic agents in cardiovascular prescriptions. Beta-blockers, ACE inhibitors, and diuretics were prominent in managing hypertension.Top of Form

查看原文本刊更多论文

三级医院冠心病处方模式

这项研究旨在评估目前在指定地点治疗冠心病（CHD）的药物处方模式，以促进专业人群的合理用药。这项观察性回顾研究在内科病房进行，历时六个月，主要针对因心脏问题向心脏病专家咨询的患者。在降血脂药物中，处方最多的是罗伐他汀（52.84%），其次是阿托伐他汀（43.15%）。抗高血压药物被广泛使用，β-受体阻滞剂、血管紧张素转换酶抑制剂和利尿剂是常用药物。肾上腺素能受体阻滞剂是治疗高血压的常用药物，其中美托洛尔（55.7%）和比索洛尔（10.8%）是常用药物。ACE 抑制剂，尤其是依那普利（65.6%），在处方中占主导地位。利尿剂，包括依普利酮（37.2%）和呋塞米（33.3%），排在第三位。大多数患者为男性，这可能与吸烟和酗酒习惯有关。分析显示，他汀类药物和抗动脉粥样硬化药物在心血管处方中很普遍。β-受体阻滞剂、血管紧张素转换酶抑制剂和利尿剂在高血压治疗中占有突出地位。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Journal of Pharmaceuticals and Health Sciences

自引率

0.00%

发文量